Urological Research Institute
The Urological Research Institute holds unique opportunities to address and investigate a variety of aspects of urogenital disorders (epidemiological, genetic, molecular, cellular, physiological and pharmacological) of immediate relevance for individual patients as well as health-care systems. Our research program aims at producing an inspiring scientific environment where clinical research and basic research in urology and urological pharmacology interact on a daily basis.
The Urological Research Institute, located in San Michele 2 building of IRCCS Ospedale San Raffaele campus, performs its activity in close collaboration with the clinical urological unit of IRCCS Ospedale San Raffaele.
URI translational research projects are possible also thanks to an impressive volume of biological samples stored in a dedicated biobank and of data collected by more than 30.000 patients during the years.
The Urological Research Institute studies a variety of urogenital pathologies, with a special focus on prostate, bladder and renal tumors, as well as sexual and reproductive dysfunctions.
Basic research projects
- Genetics factors and inheritance of prostate cancer;
- Nanotechnologies for effective delivering of chemotherapy in bladder cancer;
- Extracellular microenvironment in prostate/bladder tumors and in male infertility.
Clinical research projects
- The role of hormones as a risk and severity factor in prostate cancer;
- The efficacy of radiotherapy in urogenital tumors;
- Factors involved in the emergence of urinary incontinence and erectile dysfunction after surgery;
- Spreading patterns of metastasis from urogenital tumors;
- Conservative renal surgery and therapeutic efficacy of lymph nodes removal in urogenital tumors surgery treatment;
Group leader, Kidney cancer Unit
Staff researcher, Prostate cancer biomarkers
Group leader, Prostate cancer Unit
Staff physician scientist, Bladder cancer
Senior researcher, Prostate cancer: outcome research
Staff researcher, Long-noncoding RNA and computational research
Staff researcher, VHL syndrome and kidney cancer
Group leader, Non-oncology and rare uro-andrological diseases Unit
Staff physician scientist, Experimental onco-nephrology
Staff researcher, Extracellular vesicles and toxins
Group leader, Extracellular microenvironment Unit
Lavorgna G, Montorsi F, Salonia A. Re: Ken J. Kron, Alexander Murison, Stanley Zhou, et al. TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer. Nat Genet 2017;49:1336-45. Eur Urol. 2018 Apr;73(4):e106-e107.
Di Trapani E, Nini A, Locatelli I, Buono R, Russo A, Dell'Oglio P, Castiglione F, La Croce G, Benigni F, Montorsi F, Salonia A, Cavarretta I*, Briganti A*. Development of the first model of radical prostatectomy in the mouse: a feasibility study. Eur Urol. 2018 Mar; 73(3):482–484.
Cavarretta I, Ferrarese R, Cazzaniga W, Saita D, Lucianò R, Ceresola ER, Locatelli I, Visconti L, Lavorgna G, Briganti A, Nebuloni M, Doglioni C, Clementi M, Montorsi F, Canducci F, Salonia A. The microbiome of the prostate tumor microenvironment. 2017 Eur Urol. 72:625-631.
Trevisani F, Larcher A, Cinque A, Capitanio U, Ripa F, Vago R, Bettiga A, Benigni F, Carenzi C, Muttin F, Bertini R, Briganti A, Salonia A, Rampoldi L, Montorsi F. The association of uromodulin genotype with renal cancer aggressiveness. Eur. Urol. Focus. 2017 May; S2405-4569(17):30115-3.
Giacomini E, Vago R, Sanchez AM, Podini P, Zarovni N, Murdica V, Rizzo R, Bortolotti D, Candiani M, Viganò P. Secretome of in vitro cultured human embryos contains extracellular vesicles that are uptaken by the maternal side. Sci. Rep. 2017 Jul 12;7(1):5210.
Alfano M, Ventimiglia E, Locatelli I, Capogrosso P, Cazzaniga W, Pederzoli F, Frego N, Matloob R, Saccà A, Pagliardini L, Viganò P, Zerbi P, Nebuloni M, Pontillo M, Montorsi F, Salonia A. Anti-Mullerian hormone-to-testosterone ratio is predictive of positive sperm retrieval in men with idiopathic non-obstructive azoospermia. Sci Rep. 2017 Dec 15;7(1):17638.
Alfano M, Nebuloni M, Zerbi P, Salonia A. Male infertility and ageing: two faces of the same coin? Biochimica Clinica 2017, 41 (4).
Nini A, Capitanio U, Larcher A, Dell'Oglio P, Dehò F, Suardi N, Muttin F, Carenzi C, Freschi M, Lucianò R, La Croce G, Briganti A, Colombo R, Salonia A, Castiglioni A, Rigatti P, Montorsi F, Bertini R. Perioperative and oncologic outcomes of nephrectomy and caval thrombectomy using extracorporeal circulation and deep hypothermic circulatory arrest for renal cell carcinoma invading the supradiaphragmatic inferior vena cava and/or right atrium. Eur Urol. 2017 Sep 13. pii: S0302-2838(17)30712-1.
Larcher A, Muttin F, Fossati N, Dell'Oglio P, Di Trapani E, Stabile A, Ripa F, Trevisani F, Carenzi C, Picchio M, Briganti A, Salonia A, Mottrie A, Bertini R, Montorsi F, Capitanio U. When to perform preoperative bone scintigraphy for kidney cancer staging: indications for preoperative bone scintigraphy. Urology 2017 Dec;110:114-120.
Dell'Oglio P, Larcher A, Muttin F, Di Trapani E, Trevisani F, Ripa F, Carenzi C, Briganti A, Salonia A, Montorsi F, Bertini R, Capitanio U. Lymph node dissection should not be dismissed in case of localized renal cell carcinoma in the presence of larger diseases. Urol Oncol. 2017 Nov;35(11):662.e9-662.e15.
- Lavorgna G, et al., Re: Exercise and Cancer Treatment: Balancing Patient Needs. Lancet Oncol 2018;19:715: Cancer Prevention and Treatment: More than Exercising., Eur Urol., 2018, 74(5)
Giovanni Lavorgna, senior researcher at Prostate cancer Unit of the Urological Research Insititute (URI), Andrea Salonia, director of URI and head of Sexual-reproductive medicine and functional urology Unit, and Francesco Montorsi, head physician of Urological operative Unit, commented in a Letter to the Editor the editorial “Exercise and cancer treatment: balancing patient needs” in The Lancet Oncology, which outlines the importance of physical exercise by cancer patients both as a treatment and as a preventive measure. However, the article also raises concerns about the feasibility of such an approach in the whole pool of unselected cancer patients, because the often-weakening effects of any treatment with curative intent, possibly coupled to patient fragility and comorbidity, could reduce the proportion of eligible individuals.
- Lavorgna G., et al., Re: Jinjing Chen, Ilaria Guccini, Diletta Di Mitri, et al. Compartmentalized Activities of the Pyruvate Dehydrogenase Complex Sustain Lipogenesis in Prostate Cancer. Nat Genet 2018;50:219-28: Lipid Metabolism in Prostate Cancer: Expanding Patient Therapeutic Opportunities., Eur Urol., 2018, 74(1)
Giovanni Lavorgna, senior researcher at Prostate cancer Unit of the Urological Research Insititute (URI), Andrea Salonia, director of URI and head of Sexual-reproductive medicine and functional urology Unit, and Francesco Montorsi, head physician of Urological operative Unit, commented the two back-to-back Nature Genetics papers by Chen et al's groups concerning the genetics of lipid metabolism in prostate cancer (PCa). These manuscripts describe the effects of genomic changes on the capability of PCa cells to synthesize lipids.
- Lavorgna G., et al., Re: Ken J. Kron, Alexander Murison, Stanley Zhou, et al. TMPRSS2-ERG Fusion Co-opts Master Transcription Factors and Activates NOTCH Signaling in Primary Prostate Cancer. Nat Genet 2017;49:1336-45, Eur Urol., 2018, 73(4)
Giovanni Lavorgna, senior researcher at Prostate cancer Unit of the Urological Research Insititute (URI), Andrea Salonia, director of URI and head of Sexual-reproductive medicine and functional urology Unit, and Francesco Montorsi, head physician of Urological operative Unit, appreciated in a Letter to the Editor the report by Kron and colleagues, who used a combination of different genomic profiling approaches on tumor samples to demonstrate that modified chromatin states lead to greater ERG transcription in patients harboring the TMPRSS2-ERG (T2E) fusion gene.
- A Horizon 2020 project won by Massimo Alfano
Massimo Alfano, senior researcher at Bladder cancer Unit at the Urological Research Institute, won a Horizon 2020 project as coordinators. The project, started on 1 October 2018, is about novel precision technological platforms to promote non-invasive early diagnosis, eradication and prevention of cancer relapse: proof of concept in the bladder carcinoma.